From HAE Brazil (Abranghe)
From January to August 2022, the number of diagnosed patients in Brazil has grown from 1,796 to 1,815. The number of members of HAE Brazil (ABRANGHE) has also increased during the same period – from 2,327 to the round figure of 2,400. Until recently, HAE patients in Brazil had access to Berinert, Firazyr, Cinryze, and Takhzyro, but now HAEGARDA has been added to the modern medications available for treating HAE.
During the first half of the year, the Brazilian organization participated in several virtual events, such as a Latin American meeting of HAE patients and doctors, the release of updates to the Brazilian HAE guidelines, as well as the 4th Forum on Rare Diseases of the Federal Council of Medicine.
Most recently, ABRANGHE took part in the 7th Edition of the Rare Disease Scenario in Brazil, promoted by Casa Hunter. The event included four debate tables with patients, family members, associations, academics, the pharmaceutical industry, and regulatory bodies. The topics presented were of great importance to the knowledge of the participants.
